F. Chossat

发表

123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging

A. Veyre, N. Moins, J. Papon, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Physical and biological dosimetry in patients undergoing radiosynoviorthesis with erbium-169 and rhenium-186

M. Di Paola, A. Kahan, F. Chossat, 2001, Nuclear medicine communications.

Better results with rhenium-186 radiosynoviorthesis than with cortivazol in rheumatoid arthritis (RA): a two-year follow-up randomized controlled multicentre study.

Y. Rycke, A. Kahan, A. Bonmartin, 2004, Clinical and experimental rheumatology.

169Erbium-citrate synoviorthesis after failure of local corticosteroid injections to treat rheumatoid arthritis-affected finger joints.

A. Kahan, A. Bonmartin, Y. De rycke, 2004, Clinical and experimental rheumatology.

Quantitative analysis of striatal dopamine D2 receptors with 123I-iodolisuride SPECT in degenerative extrapyramidal diseases

B. Giraudeau, J. Cottier, D. Guilloteau, 2001, Nuclear medicine communications.

Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide).

A. Veyre, J. Madelmont, P. Souteyrand, 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

99mTc-besilesomab (Scintimun®) in peripheral osteomyelitis: comparison with 99mTc-labelled white blood cells

H. Amthauer, D. Le Guludec, A. Signore, 2011, European Journal of Nuclear Medicine and Molecular Imaging.

Myocardial perfusion imaging with technetium-99m-Tc NOET: comparison with thallium-201 and coronary angiography.

D. Le Guludec, F. Brunotte, J. Wolf, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Biodistribution, dosimetry, and safety of myocardial perfusion imaging agent 99mTcN-NOET in healthy volunteers.

R. Pasqualini, G. Vanzetto, D. Fagret, 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Clinical study of [123I] N-(2-diethylaminoethyl)-4-iodobenzamide in the diagnosis of primary and metastatic ocular melanoma.

A. Veyre, M. Moreau, J. Bonafous, 1998, Acta ophthalmologica.

[18F]DCFPyL PET/CT versus [18F]fluoromethylcholine PET/CT in Biochemical Recurrence of Prostate Cancer (PYTHON): a prospective, open label, cross-over, comparative study.

P. Maksud, C. Merlin, P. Olivier, 2023, European journal of nuclear medicine and molecular imaging.

[Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma].

A. Veyre, N. Moins, M. D’Incan, 2004, Journal francais d'ophtalmologie.